Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.